Male-female Differences in Immunohistological and Biomechanical Properties of the Thoracic Aorta
MAFATS
1 other identifier
observational
30
1 country
1
Brief Summary
Thoracic aortic aneurysms (TAA) result from progressive dilatation of the thoracic aorta and confer a risk for aortic dissection or rupture, which is associated with significant morbidity and mortality. In the Netherlands there are an estimated 200.000 adults with TAA, and annually 600 deaths after aortic dissection or rupture. There are clear differences in the incidence of TAA between men and women, with a higher incidence in men. Little is known on possible differences in outcome between male and female patients with Thoracic Aortic Aneurysm (TAA). Aortic disease is thought to affect men more frequently than women, and aortic growth is different between men and women. Current data suggest that women are at an increased risk of both dying from aortic dissection and having aorta-related complications compared to men (1). The mechanisms for these male-female difference in TAA outcome remain, however, unclear. The timing of preventive surgery is now not different for men and women, but gender-based cut-off values for maximal aortic diameter based on differences in vessel wall composition might be needed.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Feb 2021
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2021
CompletedFirst Submitted
Initial submission to the registry
June 7, 2022
CompletedFirst Posted
Study publicly available on registry
December 14, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 16, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2023
CompletedFebruary 22, 2023
February 1, 2023
1.9 years
June 7, 2022
February 21, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Male-female differences in immunohistochemical and mass spectrometry-based estrogen and testosterone receptor expression levels (and density) in the proximal aortic wall
To investigate male-female differences in estrogen receptor (ESR-alpha and ESRbeta) and testosterone receptor (AR) tissue expression in the wall of the aortic root and ascending aorta by immunohistochemical techniques and mass spectometry. Comparisons will be made using a students t-test.
1 year
Secondary Outcomes (1)
Male-female differences in immunohistochemical or mass spectrometry-based sex hormone receptor expression levels (and density) in the proximal aortic wall.
1 year
Study Arms (1)
Sample collection aortic tissue
Sample collection thoracic aorta tissue
Eligibility Criteria
Adults (≥18 years old) who will undergo or already underwent elective surgery for thoracic aortic aneurysm at Erasmus MC, Rotterdam and LUMC, Leiden.
You may qualify if:
- Adult patients (≥ 18 years old) who have a thoracic aortic aneurysm and are scheduled for elective thoracic aortic surgery in the Erasmus MC or the LUMC.
You may not qualify if:
- Patients with a known connective tissue disease (e.g. Marfan Syndrome and Ehlers-Danlos syndromes).
- Connective tissue disease,
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Erasmus MC
Rotterdam, 3000 CA, Netherlands
Biospecimen
Thoracic aorta (residual tissue).
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Hanneke Takkenberg, Prof. dr.
Erasmus Medical Center
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Prof. dr.
Study Record Dates
First Submitted
June 7, 2022
First Posted
December 14, 2022
Study Start
February 1, 2021
Primary Completion
December 16, 2022
Study Completion
December 31, 2023
Last Updated
February 22, 2023
Record last verified: 2023-02
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ICF
- Time Frame
- Data will become available upon request after a period of twelve months from the date of publication. The length of availability of IPD will depend on and therefore be based on the request of the researchers.
- Access Criteria
- IPD will be shared with scientific researchers and is dependent on the research questions. The analysis and interpretation by the researcher will be checked by the project leader before any submission of the manuscript.
All our anonymised individual patient data (IPD) will be available to other researchers, upon reasonable request and after publication of the manuscript. This includes IPD derived from all analyses that were performed for and used in this study.